

Thor Medical ships first product sample to potential customer from Herøya pilot facilities

19.11.2024 07:30:00 CET | Thor Medical ASA | Non-regulatory press releases

Oslo, November 19, 2024: Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, today ships the first product samples of Thorium-228 alpha-emitters from its newly commissioned pilot facilities at Herøya. The shipment marks another important milestone in Thor Medical's journey toward commercial operations.

"Since opening our pilot facilities at Herøya less than two months ago, our highest priority has been to ensure process and product quality. Targeted cancer care with alpha-emitters holds the potential to transform cancer treatment regimes, and this successful first production run marks another significant step towards commercially viable production of alpha-emitters", says Jasper Kurth, CEO of Thor Medical.

The first Thorium-228 product samples are today being shipped to an undisclosed potential customer, one of several potential customers for supply of Thorium-228 from Thor Medical.

The first product shipment follows other recent key de-risking milestones, including the on-time and on-budget completion of the Herøya pilot facilities in September, and the signing of a strategic 5-year supply agreement for Thorium-228 with ARTBIO in October.

On 25 November, Thor Medical hosts a Capital Markets Update in Stockholm, including presentations from both Thor Medical and ARTBIO.

Contacts

• Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com

About Thor Medical ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no.

Attachments

Download announcement as PDF.pdf